Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H9Cl2N3O |
Molecular Weight | 246.093 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl
InChI
InChIKey=INJOMKTZOLKMBF-UHFFFAOYSA-N
InChI=1S/C9H9Cl2N3O/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13/h1-3H,4H2,(H4,12,13,14,15)
Molecular Formula | C9H9Cl2N3O |
Molecular Weight | 246.093 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1867 |
7.03 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TENEX Approved UseTenex (guanfacine hydrochloride) is indicated in the management of hypertension. Tenex may be given
alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. Launch Date5.30755191E11 |
|||
Primary | TENEX Approved UseINTUNIV® is a central alpha2A-adrenergic receptor agonist indicated
for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)
as monotherapy and as adjunctive therapy to stimulant medications Launch Date5.30755191E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7 ng/mL |
4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
GUANFACINE plasma | Homo sapiens population: UNKNOWN age: ADOLESCENT sex: UNKNOWN food status: UNKNOWN |
|
10 ng/mL |
4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
GUANFACINE plasma | Homo sapiens population: UNKNOWN age: CHILD sex: UNKNOWN food status: UNKNOWN |
|
2.5 ng/mL |
1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
GUANFACINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
116 ng × h/mL |
4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
GUANFACINE plasma | Homo sapiens population: UNKNOWN age: ADOLESCENT sex: UNKNOWN food status: UNKNOWN |
|
162 ng × h/mL |
4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
GUANFACINE plasma | Homo sapiens population: UNKNOWN age: CHILD sex: UNKNOWN food status: UNKNOWN |
|
56 ng × h/mL |
1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
GUANFACINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
16 h |
1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
GUANFACINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
30% |
1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
GUANFACINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
12 mg single, oral Overdose |
unhealthy, 12 years n = 1 Health Status: unhealthy Condition: ADHD and Tourette syndrome Age Group: 12 years Sex: M Population Size: 1 Sources: |
Disc. AE: Hypertensive... AEs leading to discontinuation/dose reduction: Hypertensive (1%) Sources: |
80 mg single, oral Overdose |
unhealthy, 17 years n = 1 Health Status: unhealthy Condition: ADHD Age Group: 17 years Sex: M Population Size: 1 Sources: |
Disc. AE: Cardiogenic pulmonary edema... AEs leading to discontinuation/dose reduction: Cardiogenic pulmonary edema (1%) Sources: |
4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
unhealthy, children and adolescents n = 513 Health Status: unhealthy Condition: ADHD Age Group: children and adolescents Sex: M+F Population Size: 513 Sources: |
Disc. AE: Somnolence, Fatigue... AEs leading to discontinuation/dose reduction: Somnolence (6%) Sources: Fatigue (2%) Hypotension (1%) Headache (1%) Dizziness (1%) |
4 mg 1 times / day steady, oral Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
unhealthy, children n = 16 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: children Population Size: 16 Sources: |
Other AEs: Sedation, Fatigue... Other AEs: Sedation (below serious, 5 patients) Sources: Fatigue (below serious, 3 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypertensive | 1% Disc. AE |
12 mg single, oral Overdose |
unhealthy, 12 years n = 1 Health Status: unhealthy Condition: ADHD and Tourette syndrome Age Group: 12 years Sex: M Population Size: 1 Sources: |
Cardiogenic pulmonary edema | 1% Disc. AE |
80 mg single, oral Overdose |
unhealthy, 17 years n = 1 Health Status: unhealthy Condition: ADHD Age Group: 17 years Sex: M Population Size: 1 Sources: |
Dizziness | 1% Disc. AE |
4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
unhealthy, children and adolescents n = 513 Health Status: unhealthy Condition: ADHD Age Group: children and adolescents Sex: M+F Population Size: 513 Sources: |
Headache | 1% Disc. AE |
4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
unhealthy, children and adolescents n = 513 Health Status: unhealthy Condition: ADHD Age Group: children and adolescents Sex: M+F Population Size: 513 Sources: |
Hypotension | 1% Disc. AE |
4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
unhealthy, children and adolescents n = 513 Health Status: unhealthy Condition: ADHD Age Group: children and adolescents Sex: M+F Population Size: 513 Sources: |
Fatigue | 2% Disc. AE |
4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
unhealthy, children and adolescents n = 513 Health Status: unhealthy Condition: ADHD Age Group: children and adolescents Sex: M+F Population Size: 513 Sources: |
Somnolence | 6% Disc. AE |
4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
unhealthy, children and adolescents n = 513 Health Status: unhealthy Condition: ADHD Age Group: children and adolescents Sex: M+F Population Size: 513 Sources: |
Fatigue | below serious, 3 patients | 4 mg 1 times / day steady, oral Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
unhealthy, children n = 16 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: children Population Size: 16 Sources: |
Sedation | below serious, 5 patients | 4 mg 1 times / day steady, oral Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
unhealthy, children n = 16 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: children Population Size: 16 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 16.0 |
no | |||
Page: 15.0 |
no | |||
Page: 16.0 |
no | |||
Page: 16.0 |
no | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 16.0 |
no | |||
Page: 15.0 |
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 10.0 |
major | yes (co-administration study) Comment: There was a significant decrease in the rate and extent of guanfacine exposure when co-administered with rifampin, a CYP3A4 inducer. The exposure to guanfacine decreased by 70% (AUC) Page: 10.0 |
||
Page: 18.0 |
weak | |||
Page: 10.0 |
yes | yes (co-administration study) Comment: There was a substantial increase in the rate and extent of guanfacine exposure when administered with ketoconazole; the guanfacine exposure increased 3-fold (AUC) Page: 10.0 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Guanfacine and secondary mania in children. | 1999 Aug |
|
Centrally acting imidazoline I1-receptor agonists: do they have a place in the management of hypertension? | 2001 |
|
Respiratory pattern and hypoxic ventilatory response in mice functionally lacking alpha2A-adrenergic receptors. | 2001 |
|
Effects of alpha(2)-adrenergic agonists on lipopolysaccharide-induced aqueous flare elevation in pigmented rabbits. | 2001 May-Jun |
|
Presynaptic autoregulation of norepinephrine release from the sympathetic nerve fibers in the pineal gland of the domestic pig. Pharmacological characterization of alpha(2)adrenoceptors mediating this process. | 2002 Apr |
|
Testosterone dependence of salt-induced hypertension in Sabra rats and role of renal alpha(2)-adrenoceptor subtypes. | 2002 Jan |
|
Epidemiology and toxicity of pediatric guanfacine exposures. | 2002 Nov |
|
Stimulation of interleukin-12 production in mouse macrophages via activation of p38 mitogen-activated protein kinase by alpha2-adrenoceptor agonists. | 2003 Apr 25 |
|
Hallucinations associated with initiation of guanfacine. | 2003 Dec |
|
Growth hormone response to guanfacine in boys with attention deficit hyperactivity disorder: a preliminary study. | 2003 Fall |
|
An antihypokinesic action of alpha2-adrenoceptors upon MPTP-induced behaviour deficits in mice. | 2003 Feb |
|
Pharmacological characterization of unique prazosin-binding sites in human kidney. | 2003 Jul |
|
Pharmacotherapy of pervasive developmental disorders in children and adolescents. | 2004 |
|
The alpha(2A)-adrenergic agonist guanfacine improves visuomotor associative learning in monkeys. | 2004 Jan |
|
[Centrally-acting antihypertensive drugs]. | 2004 Mar |
|
Loss of glutamatergic pyramidal neurons in frontal and temporal cortex resulting from attenuation of FGFR1 signaling is associated with spontaneous hyperactivity in mice. | 2004 Mar 3 |
|
Potential noradrenergic targets for cognitive enhancement in schizophrenia. | 2004 May |
|
Methylphenidate an effective treatment for ADHD? | 2004 Oct |
|
Pulse-synchronous sympathetic burst power as a new index of sympathoexcitation in patients with heart failure. | 2004 Oct |
|
Alpha2 adrenergic agonists for the management of opioid withdrawal. | 2004 Oct 18 |
|
Alpha-2 adrenoceptor activation inhibits phencyclidine-induced deficits of spatial working memory in rats. | 2005 Aug |
|
Aripiprazole in children and adolescents: clinical experience. | 2005 Jul |
|
The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder. | 2005 Mar |
|
Central sympathetic inhibition augments sleep-related ultradian rhythm of parasympathetic tone in patients with chronic heart failure. | 2005 Sep |
|
Mechanism of action of agents used in attention-deficit/hyperactivity disorder. | 2006 |
|
Tourette's Syndrome. | 2006 Jun |
|
Syncope in children with Tourette's syndrome treated with guanfacine. | 2006 Mar |
|
Differential noradrenergic influence on seizure expression in genetically Fast and Slow kindling rat strains during massed trial stimulation of the amygdala. | 2007 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/guanfacine.html
Usual Adult Dose for Hypertension
Initial dose: 1 mg orally once a day at bedtime; may increase to 2 mg once a day if satisfactory result not achieved after 3 to 4 weeks.
Usual Pediatric Dose for Attention Deficit Disorder
6 YEARS TO LESS THAN 18 YEARS:
Initial dose: 1 mg orally once a day, either in the morning or evening, at approximately the same time each day; may adjust in increments of no more than 1 mg/week.
Recommended target dose: 0.05 to 0.12 mg/kg/day (total daily dose between 1 and 7 mg) once a day, depending on clinical response and tolerability
Maximum dose: 6 to 12 years: Doses above 4 mg/day have not been evaluated; 13 to 17 years: Doses above 7 mg/day have not been evaluated.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2884339
Guanfacine and clonidine at relatively high concentrations (10(-6)-10(-4) M) produced contractions of the rat vas deferens which were antagonized by prazosin.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:44:04 UTC 2023
by
admin
on
Wed Jul 05 22:44:04 UTC 2023
|
Record UNII |
30OMY4G3MK
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175554
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
||
|
FDA ORPHAN DRUG |
124199
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
||
|
NDF-RT |
N0000009918
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
||
|
WHO-ATC |
C02AC02
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
||
|
NCI_THESAURUS |
C270
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
||
|
FDA ORPHAN DRUG |
405313
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
||
|
WHO-VATC |
QC02AC02
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
||
|
LIVERTOX |
NBK548586
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Guanfacine
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
PRIMARY | |||
|
30OMY4G3MK
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
PRIMARY | |||
|
30OMY4G3MK
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
PRIMARY | |||
|
522
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
PRIMARY | |||
|
CHEMBL862
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
PRIMARY | |||
|
759121
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
PRIMARY | |||
|
DTXSID9046944
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
PRIMARY | |||
|
DB01018
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
PRIMARY | |||
|
40114
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
PRIMARY | RxNorm | ||
|
29110-47-2
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
PRIMARY | |||
|
D016316
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
PRIMARY | |||
|
1343
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
PRIMARY | |||
|
M5866
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
PRIMARY | Merck Index | ||
|
3999
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
PRIMARY | |||
|
249-442-8
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
PRIMARY | |||
|
100000084474
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
PRIMARY | |||
|
SUB07985MIG
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
PRIMARY | |||
|
3519
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
PRIMARY | |||
|
C61779
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
PRIMARY | |||
|
GUANFACINE
Created by
admin on Wed Jul 05 22:44:04 UTC 2023 , Edited by admin on Wed Jul 05 22:44:04 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> AGONIST |
SHORT-ACTING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||